A Double Blind (3rd Party Open) Randomized, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of Repeat Doses PF-06305591 Combined With a Cross-over Relative Bioavailability and Food Effect Evaluation After Single Dose of PF-06305591 in Healthy Young Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2013
At a glance
- Drugs PF 6305591 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 02 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Nov 2013 Planned End Date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 18 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.